Ipsen S.A. Stock
Price
Target price
€111.10
€111.10
1.750%
1.9
1.750%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Ipsen S.A. Stock
Ipsen S.A. gained 1.750% today.
So far the community has only identified positive things for Ipsen S.A. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Ipsen S.A. in the next few years
Pros
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ipsen S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ipsen S.A. | 1.750% | 0.090% | 1.092% | 17.194% | 9.891% | 52.401% | -18.309% |
| Sanofi S.A. | 1.650% | -2.750% | -1.237% | -3.650% | 6.078% | 7.241% | 44.765% |
| Biogen Inc. | -0.070% | 0.718% | -0.214% | 51.863% | 9.467% | 3.450% | 10.817% |
| Pfizer Inc. | 1.560% | 2.282% | 0.986% | -26.896% | -25.125% | 16.623% | 21.537% |
Comments
News
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
Regulatory News:
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application for palovarotene, an investigational treatment for the
